US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
US5576311A
(en)
*
|
1994-11-30 |
1996-11-19 |
Pharmos Corporation |
Cyclodextrins as suspending agents for pharmaceutical suspensions
|
US5976573A
(en)
*
|
1996-07-03 |
1999-11-02 |
Rorer Pharmaceutical Products Inc. |
Aqueous-based pharmaceutical composition
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
US5955097A
(en)
|
1996-10-18 |
1999-09-21 |
Virotex Corporation |
Pharmaceutical preparation applicable to mucosal surfaces and body tissues
|
TW503113B
(en)
|
1997-01-16 |
2002-09-21 |
Senju Pharma Co |
Aqueous suspension for nasal administration
|
KR100508227B1
(ko)
*
|
1997-03-14 |
2006-03-23 |
센주 세이야꾸 가부시키가이샤 |
로테프레드놀에타보네이트수성현탁액
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
SE9704186D0
(sv)
*
|
1997-11-14 |
1997-11-14 |
Astra Ab |
New composition of matter
|
CA2318642A1
(en)
*
|
1998-01-22 |
1999-07-29 |
Santen Pharmaceutical Co., Ltd. |
Fluorometholone ophthalmic suspension
|
US6103266A
(en)
*
|
1998-04-22 |
2000-08-15 |
Tapolsky; Gilles H. |
Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
|
CA2342797A1
(en)
*
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
US6395746B1
(en)
|
1998-09-30 |
2002-05-28 |
Alcon Manufacturing, Ltd. |
Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
|
US6716830B2
(en)
|
1998-09-30 |
2004-04-06 |
Alcon, Inc. |
Ophthalmic antibiotic compositions containing moxifloxacin
|
US6509327B1
(en)
|
1998-09-30 |
2003-01-21 |
Alcon Manufacturing, Ltd. |
Compositions and methods for treating otic, ophthalmic and nasal infections
|
EP1194145B1
(de)
*
|
1999-06-22 |
2003-02-05 |
Boehringer Ingelheim International Gmbh |
Stabile xylometazolin- und oxymetazolinlösung
|
FR2796553B1
(fr)
*
|
1999-07-22 |
2001-09-28 |
Warner Lambert Co |
Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
|
PL201130B1
(pl)
|
1999-09-24 |
2009-03-31 |
Alcon Inc |
Kompozycje zawiesinowe zawierające ciprofloksacynę i deksametazon do podawania miejscowego do oczu, uszu lub nosa
|
AR026073A1
(es)
|
1999-10-20 |
2002-12-26 |
Nycomed Gmbh |
Composicion farmaceutica acuosa que contiene ciclesonida
|
AU7947600A
(en)
*
|
1999-10-20 |
2001-04-30 |
Teijin Limited |
Aqueous medicinal compositions
|
US20040097486A1
(en)
*
|
1999-11-18 |
2004-05-20 |
Yanni John M. |
Use of an H1 antagonist and a safe steroid to treat eye conditions
|
CN1376066A
(zh)
*
|
1999-11-18 |
2002-10-23 |
爱尔康公司 |
H1拮抗剂和安全类固醇的治疗眼病的用途
|
US6495534B2
(en)
*
|
2000-05-15 |
2002-12-17 |
Pharmacia & Upjohn Spa |
Stabilized aqueous suspensions for parenteral use
|
JP2003533464A
(ja)
*
|
2000-05-15 |
2003-11-11 |
フアルマシア・イタリア・エツセ・ピー・アー |
安定化ステロイド懸濁液
|
CA2412575C
(en)
|
2000-07-26 |
2009-12-29 |
Onkar N. Singh |
Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
|
EP1337237B1
(de)
*
|
2000-11-15 |
2009-03-11 |
Mohan A. Chandavarkar |
Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
|
EP1341541A4
(de)
*
|
2000-11-16 |
2004-11-17 |
Alcon Mfg Ltd |
Kombinationstherapie zur senkung und kontrolle des augeninnendrucks
|
PL212457B1
(pl)
|
2001-09-21 |
2012-10-31 |
Alcon |
Zastosowanie kombinacji ciprofloksacyny i deksametazonu
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
US20090215735A1
(en)
*
|
2002-02-25 |
2009-08-27 |
Alcon, Inc. |
Topical solution formulations containing a corticosteroid and a cyclodextrin
|
WO2004006957A1
(en)
*
|
2002-07-15 |
2004-01-22 |
Alcon, Inc. |
Pharmaceutical compositions for otic use
|
PT1551417E
(pt)
*
|
2002-10-18 |
2008-10-31 |
Aqueous Pharma Ltd |
Formulação de lágrimas com três camadas
|
US20040151754A1
(en)
*
|
2002-12-20 |
2004-08-05 |
Control Delivery Systems, Inc. |
Steroid suspensions for intraocular use
|
WO2004064828A1
(ja)
|
2003-01-21 |
2004-08-05 |
Senju Pharmaceutical Co., Ltd. |
2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤
|
US20050069590A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Buehler Gail K. |
Stable suspensions for medicinal dosages
|
US20050095205A1
(en)
*
|
2003-10-31 |
2005-05-05 |
Ramesh Krishnamoorthy |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
US20050197303A1
(en)
*
|
2003-10-31 |
2005-09-08 |
Bausch & Lomb Incorporated |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
WO2005041980A1
(en)
|
2003-11-03 |
2005-05-12 |
Ivax Corporation |
Soft steroid compositions for use in dry powder inhalers
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
WO2005053708A1
(ja)
*
|
2003-12-02 |
2005-06-16 |
Senju Pharmaceutical Co., Ltd. |
ロテプレドノールエタボネート水性懸濁液剤
|
PE20050941A1
(es)
*
|
2003-12-16 |
2005-11-08 |
Nycomed Gmbh |
Suspensiones acuosas de ciclesonida para nebulizacion
|
AU2005209201B2
(en)
*
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
WO2005072710A2
(en)
*
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
US20050182039A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Bausch & Lomb Incorporated |
Use of Loteprednol etabonate for the treatment of dry eye
|
WO2005094836A2
(en)
*
|
2004-03-25 |
2005-10-13 |
Bausch & Lomb Incorporated |
Use of loteprednol etabonate for the treatment of dry eye
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
JP2008505978A
(ja)
*
|
2004-07-12 |
2008-02-28 |
アラーガン、インコーポレイテッド |
眼病用組成物および眼病治療法
|
US8653055B2
(en)
*
|
2004-09-15 |
2014-02-18 |
Teva Animal Health, Inc. |
Corticosteroid having low systemic absorption
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
SI1885336T1
(sl)
*
|
2005-05-10 |
2009-08-31 |
Alcon Inc |
Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
|
ES2313670T3
(es)
*
|
2005-05-10 |
2009-03-01 |
Alcon Inc. |
Suspension oftalmica que comprende un farmaco oftalmico, una polioxamina y un agente glicolico ajustador de la tonicidad, uso de dicha composicion para la fabricacion de un medicamento para tratar trstornos oftalmicos.
|
EA200800949A1
(ru)
*
|
2005-09-26 |
2008-08-29 |
ПЬЕДМОН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Способы лечения и профилактики среднего отита посредством химических веществ, способствующих проникновению, для обеспечения трансмембранного поступления лекарственного средства в среднее ухо
|
AU2006295248A1
(en)
*
|
2005-09-26 |
2007-04-05 |
Piedmont Pharmaceuticals Llc |
Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
|
BRPI0613401B8
(pt)
|
2005-10-18 |
2021-05-25 |
Allergan Inc |
composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior
|
US20090082321A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Allergan, Inc. |
Steroid containing drug delivery systems
|
US20070093461A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Bausch & Lomb Incorporated |
Effect of Loteprednol etabonate on vascular dysfunction
|
WO2007058935A2
(en)
*
|
2005-11-14 |
2007-05-24 |
Bausch & Lomb Incorporated |
Ophthalmic composition for dry eye therapy
|
US7955632B2
(en)
|
2005-12-07 |
2011-06-07 |
Bayer B.V. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
US20070128251A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Piedmont Pharmaceuticals, Inc. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
WO2007112274A2
(en)
*
|
2006-03-28 |
2007-10-04 |
Javelin Pharmaceuticals, Inc. |
Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
|
KR20160033796A
(ko)
|
2006-03-28 |
2016-03-28 |
자블린 파머슈티칼스 인코포레이티드 |
저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
WO2008002118A1
(es)
*
|
2006-06-27 |
2008-01-03 |
Arturo Jimenez Bayardo |
Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
|
DK2054031T3
(en)
|
2006-07-21 |
2016-05-17 |
Biodelivery Sciences Int Inc |
Transmucosal delivery devices with improved uptake
|
WO2008027340A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
WO2008027341A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
WO2008030557A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Johns Hopkins University |
Compositions and methods for enhancing transport through mucus
|
TWI415629B
(zh)
|
2006-10-26 |
2013-11-21 |
Otsuka Pharma Co Ltd |
含有瑞巴匹特之水性醫藥懸浮物及其製造方法
|
US20080119448A1
(en)
*
|
2006-11-02 |
2008-05-22 |
Friedlaender Mitchell H |
Methods of treating an ocular allergy with low dose dexamethasone
|
WO2008057364A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Riolan Technologies, Inc. |
Method for treating blepharitis
|
CN101721714B
(zh)
*
|
2009-12-18 |
2011-12-07 |
重庆莱美药业股份有限公司 |
实体瘤被动靶向性抗癌前药及其制备方法
|
WO2011106702A2
(en)
|
2010-02-25 |
2011-09-01 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
EP2699229A2
(de)
*
|
2011-04-22 |
2014-02-26 |
Alcon Research, Ltd. |
Ophthalmische zusammensetzung mit einem viskositätsverstärkungssystem mit zwei unterschiedlichen viskositätsverstärkern
|
US8703177B2
(en)
|
2011-08-18 |
2014-04-22 |
Biodelivery Sciences International, Inc. |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
AU2012312816A1
(en)
|
2011-09-22 |
2014-04-24 |
Bausch & Lomb Incorporated |
Ophthalmic gel compositions
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
JP5883539B2
(ja)
|
2012-03-16 |
2016-03-15 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
Hif−1阻害剤の送達のための放出制御製剤
|
EP2825207B1
(de)
|
2012-03-16 |
2020-08-19 |
The Johns Hopkins University |
Nichtlineare multiblock-copolymer-arzneimittelkonjugate zur verabreichung von wirkstoffen
|
EP4008355A1
(de)
|
2012-05-03 |
2022-06-08 |
Kala Pharmaceuticals, Inc. |
Pharmazeutische nanopartikel mit verbessertem mukosalem transport
|
MX2014013315A
(es)
*
|
2012-05-03 |
2015-09-10 |
Kala Pharmaceuticals Inc |
Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
|
US9827191B2
(en)
*
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
EP2844227B1
(de)
*
|
2012-05-03 |
2020-11-18 |
Kala Pharmaceuticals, Inc. |
Pharmazeutische nanopartikel mit verbessertem mukosalem transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US9889208B2
(en)
|
2012-05-04 |
2018-02-13 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
CN103565742A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
氟米龙滴眼液
|
CN103565740A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
依碳氯替泼诺混悬滴眼液
|
WO2014124006A1
(en)
|
2013-02-05 |
2014-08-14 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
EP3763710A1
(de)
|
2013-02-20 |
2021-01-13 |
Kala Pharmaceuticals, Inc. |
Therapeutische verbindungen und verwendungen davon
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
US20150164882A1
(en)
|
2013-07-22 |
2015-06-18 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
|
US20160279055A1
(en)
|
2013-07-22 |
2016-09-29 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
|
KR20160099084A
(ko)
|
2013-11-01 |
2016-08-19 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정질 형태 및 그의 용도
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
LT3216451T
(lt)
*
|
2014-11-07 |
2022-06-27 |
Santen Pharmaceutical Co., Ltd. |
Oftalmologinė vandeninė kompozicija
|
AU2016211696B2
(en)
|
2015-01-27 |
2018-05-10 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
CN106279325A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106279324A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
CN106892952A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106892953A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
CA3036336A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
AU2017324251A1
(en)
|
2016-09-08 |
2019-03-21 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10392399B2
(en)
|
2016-09-08 |
2019-08-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US12023344B2
(en)
|
2022-05-25 |
2024-07-02 |
Famygen Life Sciences, Inc. |
Topical otic, ophthalmic, and nasal corticosteroid formulations
|